Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

Mizoguchi Kosuke; Nakamura Yoichi; Sano Kazumi; Sato Shuntaro; Ikegami Yoji; Motoshima Kohei; Takemoto Shinnosuke; Ogawara Daiki; Senju Hiroaki; Sugasaki Nanae; Ikeda Takaya; Yamaguchi Hiroyuki; Nakatomi Katsumi; Fukuda Minoru; Izumikawa Koichi; Mukae Hiroshi

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

【24h】

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

机译：吉非替尼的药代动力学参数可预测具有EGFR突变的晚期非小细胞肺癌患者的疗效和毒性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.

机译：在患有表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）患者中评估了吉非替尼的血浆浓度与抗肿瘤活性之间的关系。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2016年第2期|共6页
作者
Mizoguchi Kosuke; Nakamura Yoichi; Sano Kazumi; Sato Shuntaro; Ikegami Yoji; Motoshima Kohei; Takemoto Shinnosuke; Ogawara Daiki; Senju Hiroaki; Sugasaki Nanae; Ikeda Takaya; Yamaguchi Hiroyuki; Nakatomi Katsumi; Fukuda Minoru; Izumikawa Koichi; Mukae Hiroshi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Chemotherapy; EGFR mutations; Elimination half-life; Gefitinib; Non-small cell lung cancer; Pharmacokinetics;

机译：化学疗法;EGFR突变;消除半衰期;吉非替尼;非小细胞肺癌;药代动力学;

相似文献

外文文献
中文文献
专利

1. Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations [J] . Mizoguchi Kosuke, Nakamura Yoichi, Sano Kazumi, Cancer chemotherapy and pharmacology. . 2016,第2期

机译：吉非替尼的药代动力学参数可预测具有EGFR突变的晚期非小细胞肺癌患者的疗效和毒性
2. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer [J] . Hirose Takashi, Fujita Ken-ichi, Kusumoto Sojiro, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：吉非替尼在EGFR突变阳性晚期非小细胞肺癌患者中的药代动力学和药物基因组学与安全性和有效性的关系
3. Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations [J] . Xuhong Jiang, Xiaoqing Li, Lingli Tu, Journal of International Medical Research . 2020,第10期

机译：持续的Gefitinib Retreatment超出了患有敏感性的晚期非小细胞肺癌患者的进展<斜体> EGFR 突变
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations [O] . Minghui Zhang, Mingyang Liu, Yan Wang 2016

机译：EGFR-TKIs联合化学疗法治疗携带EGFR突变的晚期非小细胞肺癌的临床疗效
7. EP1.01-102 Efficacy and Toxicity of Erlotinib and Gefitinib in Moroccan Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation [O] . N. Benchakroun, N. Minoungou, Z. Bouchbika, 2019

机译：EP1.01-102欧洛替尼和吉非替尼在摩洛哥患者中具有EGFR突变的摩洛哥患者的疗效和毒性

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

摘要

著录项

相似文献

相关主题

期刊订阅